{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:15:17Z","timestamp":1790806517549,"version":"4.1.0"},"reference-count":44,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncology Practice"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec><jats:title>PURPOSE:<\/jats:title><jats:p> Several frameworks have been developed to define and quantify the value of oncologic therapies and to support decision making; however, they define treatment value mainly in terms of clinical benefit. As part of its mission to improve oncologic care, the ECO Foundation (Excellence and Quality in Oncology) directed this pilot study aimed at developing a reflective multicriteria decision analysis (MCDA)\u2013based framework for evaluating and positioning oncologic drugs in the clinical setting. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p> The framework was developed following Evidence and Value: Impact on Decision-Making methodology, and literature was reviewed to identify relevant criteria. The selected criteria were then presented to a group of experts composed of 9 clinical oncologists who assessed each criterion for inclusion in the framework and suggested modifications in their definition and\/or response scale. The framework was tested in 2 case studies (abemaciclib for advanced or metastatic hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative breast cancer and TAS-102 for metastatic colorectal cancer) to validate the proposed framework; this was followed by a discussion of the results. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p> Eight of the 15 criteria presented to the experts were included in the framework: disease severity, unmet needs, comparative efficacy, comparative safety\/tolerability, treatment intent, comparative treatment cost, comparative other medical costs, and quality of evidence. Framework validation in 2 drug cases resulted in similar value scores, although they were based on different contributing criteria and resulted in different clinical recommendations. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION:<\/jats:title><jats:p> We developed and validated a reflective MCDA framework for the assessment and positioning of oncologic therapies in Spain. Additional work is needed to create a manual for practical decision making in the clinical setting. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jop.19.00487","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T22:01:02Z","timestamp":1583964062000},"page":"e298-e305","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":10,"title":["Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice"],"prefix":"10.1200","volume":"16","author":[{"given":"Carlos","family":"Camps","sequence":"first","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Badia","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Omakase Consulting SL, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda-Campelo","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Complejo Hospitalario Universitario A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Garc\u00eda-Foncillas","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Spain"},{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Cl\u00ednico Universitario de Santiago de Compostela, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartomeu","family":"Massuti","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital General Universitario de Alicante, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Puerta de Hierro, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Salazar","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Institut Catal\u00e0 d\u2019Oncologia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Virizuela","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Universitario Virgen Macarena, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Guillem","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n ECO (Excelencia y Calidad en Oncolog\u00eda), Madrid, Spain"},{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Instituto Valenciano de Oncolog\u00eda, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4530"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.0462"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1011024"},{"key":"B4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jval.2016.12.004","volume":"20","author":"Refoios Camejo R","year":"2017","journal-title":"Value Health"},{"key":"B5","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1056\/NEJMc1101108","volume":"364","author":"Tilburt JC","year":"2011","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.socscimed.2017.06.024","volume":"188","author":"Angelis A","year":"2017","journal-title":"Soc Sci Med"},{"key":"B9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12325-017-0653-1","volume":"35","author":"Wagner M","year":"2018","journal-title":"Adv Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2518"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx310"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv249"},{"key":"B15","first-page":"253","volume":"10","author":"Slomiany M","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"B16","doi-asserted-by":"crossref","first-page":"e470s","DOI":"10.6061\/clinics\/2018\/e470s","volume":"73","author":"Campolina AG","year":"2018","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6894"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00729"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0177"},{"key":"B20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jval.2016.11.014","volume":"20","author":"Perfetto EM","year":"2017","journal-title":"Value Health"},{"key":"B21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1017\/S0266462318003641","volume":"35","author":"Badia X","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"B22","unstructured":"Badia X, Poveda-Andr\u00e9s JL, Merino-Montero S: Descriptive analysis of the criteria used in the evaluation reports of drugs in Spain [in Spanish]. Revista Espa\u00f1ola de Econom\u00eda de la Salud, 12:180-191, 2017. https:\/\/www.economiadelasalud.com\/pdf\/V12N1\/Originales03_EvaluacionesMCDA.pdf"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","volume":"19","author":"Thokala P","year":"2016","journal-title":"Value Health"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.6-a.s13"},{"key":"B25","first-page":"S34","volume":"23","author":"Bentley TGK","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0097-z"},{"key":"B27","author":"Sledge GW","journal-title":"JAMA Onco"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"B30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12094-016-1528-7","volume":"19","author":"Longo-Mu\u00f1oz F","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"B32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2017.10.009","volume":"90","author":"Van Cutsem E","year":"2018","journal-title":"Eur J Cancer"},{"key":"B35","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.jval.2018.09.1063","volume":"21","author":"Badia X","year":"2018","journal-title":"Value Health"},{"key":"B36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1017\/S0266462318000569","volume":"34","author":"Rold\u00e1n UB","year":"2018","journal-title":"Int J Technol Assess Health Care"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.013"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1257\/jep.29.1.139"},{"key":"B39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40273-014-0135-0","volume":"32","author":"Marsh K","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"B40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/djy079","volume":"110","author":"Leopold C","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.025106"},{"key":"B42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s41669-017-0048-x","volume":"2","author":"Garau M","year":"2018","journal-title":"Pharmacoeconom Open"},{"key":"B43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1017\/S0266462317000149","volume":"33","author":"Gilabert-Perramon A","year":"2017","journal-title":"Int J Technol Assess Health Care"},{"key":"B44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13023-016-0555-3","volume":"12","author":"Schey C","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13023-019-1121-6","volume":"14","author":"Guarga L","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B46","unstructured":"Abad MR, Camps C, Domenech-Climent N, et al: Determining value contribution of immunotherapy in oncology in Spain using multi-criteria decision analysis [in Spanish]. Revista Espa\u00f1ola de Econom\u00eda de la Salud, 13(5):852-867, 2018. https:\/\/www.economiadelasalud.com\/pdf\/V13N5\/Original01_ValInmunoterapia.pdf"},{"key":"B47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40259-018-0284-3","volume":"32","author":"Zozaya N","year":"2018","journal-title":"BioDrugs"},{"key":"B48","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13023-018-0966-4","volume":"13","author":"Jim\u00e9nez A","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B49","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2147\/CEOR.S189436","volume":"11","author":"Bretoni A","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"B50","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12885-017-3258-9","volume":"17","author":"Wagner M","year":"2017","journal-title":"BMC Cancer"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JOP.19.00487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:02:10Z","timestamp":1653818530000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JOP.19.00487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1200\/JOP.19.00487"],"URL":"https:\/\/doi.org\/10.1200\/jop.19.00487","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"2020-01-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}